Last reviewed · How we verify
didanosine + lamivudine + efavirenz
didanosine + lamivudine + efavirenz is a Antiretroviral combination therapy (NRTI + NNRTI) Small molecule drug developed by Clinical Trial Agency of HIV Study Group. It is currently FDA-approved for HIV-1 infection.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes required for viral reproduction.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes required for viral reproduction. Used for HIV-1 infection.
At a glance
| Generic name | didanosine + lamivudine + efavirenz |
|---|---|
| Sponsor | Clinical Trial Agency of HIV Study Group |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Didanosine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural nucleotides to terminate viral DNA chain elongation. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds and inhibits the reverse transcriptase enzyme. Together, they suppress HIV viral load by targeting multiple steps of the viral replication cycle.
Approved indications
- HIV-1 infection
Common side effects
- Peripheral neuropathy
- Dizziness/CNS effects
- Rash
- Pancreatitis
- Hepatotoxicity
- Nausea
- Lipodystrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- A Prospective Cohort of Children With HIV Infection
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (PHASE3)
- Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV (NA)
- The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs (PHASE2)
- Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- didanosine + lamivudine + efavirenz CI brief — competitive landscape report
- didanosine + lamivudine + efavirenz updates RSS · CI watch RSS
- Clinical Trial Agency of HIV Study Group portfolio CI
Frequently asked questions about didanosine + lamivudine + efavirenz
What is didanosine + lamivudine + efavirenz?
How does didanosine + lamivudine + efavirenz work?
What is didanosine + lamivudine + efavirenz used for?
Who makes didanosine + lamivudine + efavirenz?
What drug class is didanosine + lamivudine + efavirenz in?
What development phase is didanosine + lamivudine + efavirenz in?
What are the side effects of didanosine + lamivudine + efavirenz?
What does didanosine + lamivudine + efavirenz target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Clinical Trial Agency of HIV Study Group — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Compare: didanosine + lamivudine + efavirenz vs similar drugs
- Pricing: didanosine + lamivudine + efavirenz cost, discount & access